Xiang Sun

Rivaroxaban in Patients with a Recent Acute Coronary Syndrome

Jessica L. Mega, Eugene Braunwald, Stephen D. Wiviott et al. · New England Journal of Medicine · 2011 · 1.9K citations · Full text

Medicine, Cardiology, Pharmacology +13

Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial

E. Magnus Ohman, Matthew T. Roe, Philippe Gabríel Steg et al. · The Lancet · 2017 · 219 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Topiramate: Long‐Term Maintenance of Weight Loss Induced by a Low‐Calorie Diet in Obese Subjects

Arne Astrup, Ian D. Caterson, Pierre Zelissen et al. · Obesity Research · 2004 · 141 citations

Agriculture, Pharmacology, Pharmacotherapy +17

Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome

C. Michael Gibson, Jessica L. Mega, Paul Burton et al. · American Heart Journal · 2011 · 95 citations

Medicine, Cardiology, Pharmacology +17

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Topiramate Controlled Release in the Treatment of Obese Type 2 Diabetic Patients

Julio Rosenstock, Priscilla Hollander, Kishore M. Gadde et al. · Diabetes Care · 2007 · 85 citations · Full text

Pharmacy, Endocrinology, Pharmacotherapy +17